Elkfork Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Elkfork Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$21K	Hold	264	–	–	﹤0.01%	1029
2019 Q2	$25K	Buy	264 +110	+71%	+$9.5K	﹤0.01%	1025
2019 Q1	$13K	Sell	154 -44	-22%	-$3.65K	﹤0.01%	1027
2018 Q4	$11K	Buy	+198	New	+$12.1K	﹤0.01%	1005

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Elkfork Partners's RETA Position: Q3 2019 in Review

Elkfork Partners held its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) position steady in Q3 2019 at 264 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Elkfork Partners first reported a position in RETA in Q4 2018 and has held it in 4 quarters since. The position peaked at $25K in Q2 2019. 164 funds tracked by Wall St. Rank hold RETA as of Q3 2019.

Elkfork Partners held 264 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $21K as of Q3 2019.
Elkfork Partners left its Reata Pharmaceuticals, Inc. Class A Common Stock share count unchanged in Q3 2019.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1029 holding.
Elkfork Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and has held it in 4 quarters since.
Elkfork Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $25K in Q2 2019.
164 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.